Prime Medicine GAAP EPS of -$0.44 misses by $0.01, revenue of $0.21M misses by $5.7M

by


  • Prime Medicine press release (NASDAQ:PRME): Q3 GAAP EPS of -$0.44 misses by $0.01.
  • Revenue of $0.21M misses by $5.7M.
  • As of September 30, 2024, pro-forma cash, cash equivalents, investments and restricted cash were $244.6 million. Cash, cash equivalents, investments, and restricted cash were $189.6 million, as compared to $135.2 million as of


Leave a Comment